Tweets

	U.S. FDA @US_FDA	9h
	#FDAVoices FDA engages with cancer patients and advocacy groups and encourages research into the measurement of patient experiences so that we can use this information to generate science-based recommendations for patient-centered regulatory policy go.usa.gov/xEmM7 pic.twitter.com/pwJjYeNvkl
	View photo ·

	U.S. FDA @US_FDA	10h
	Secondhand smoke causes more than 30,000 coronary heart disease deaths in the U.S. per year. During #heartmonth find out more about free text messaging programs to help you get and stay smoke-free. smokefree.gov/tools-tips/tex… via @FDATobacco pic.twitter.com/Dm93HiwpZC
	View photo ·

	U.S. FDA @US_FDA	11h
	That's it for the #NIHchat. Thanks to @NIH for hosting! twitter.com/NIH/status/109…
	View details ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A6: #FDA is developing a series of methodological guidance on the collection of patient experience data, and the use of such data and related information in drug development. To learn more, please visit: fda.gov/Drugs/Developm…. #PFDD pic.twitter.com/Ou8OgHTzFw
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A6: #FDA has recently issued draft guidance on ways stakeholders can help advance drug development by sharing patient experience data. For more information, please visit: fda.gov/Drugs/Developm…. Comments on the draft guidance are due by March 21st. #PFDD pic.twitter.com/UCGu4UlPnq
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A6: #FDA Orphan incentives include clinical trial tax credits, fee waivers, and marketing exclusivity Link to designation program page. #NIHChat
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A6: DYK FDA has a webinar on tips for creating an orphan-drug designation application at go.usa.gov/xEmsv. Also view #FDA’s orphan-drug designation application form at go.usa.gov/xEmsf. #NIHChat
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A6: Join us March 15 for the 2019 FDA Oncology Center of Excellence Childhood Cancer Advocacy Forum (in person or online). Register now: bit.ly/2GxJwgd #NIHChat pic.twitter.com/0XGQuESVOc
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A6: Read FDA/CDER’s “Advancing Health Through Innovation: 2018 New Drug Therapy Approvals” report to learn about important new drug approvals in 2018 & innovative regulatory tools go.usa.gov/xE2d7 #NIHChat
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A6: Learn more about HUDs visit - bit.ly/2miedI1 #NIHChat
	View conversation ·

	U.S. FDA @US_FDA	11h
	A6: Have you seen #FDA video that describes how #FDA is administering funding to support innovative clinical trial methods and research for the millions of people with rare diseases? #NIHChat youtube.com/watch?v=QqJjkn…
	View details ·

	U.S. FDA retweeted
	FDA Patient Affairs @FDAPatientinfo	11h
	A6. Are you a patient, caregiver, or advocate who wants to connect with FDA, and don’t know where to begin? Patient Affairs can help! Connect with us go.usa.gov/xEECp #NIHchat twitter.com/NIH/status/109…
	View details ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA FDA plans to hold a public meeting to obtain input on the impacts of rare diseases on daily life and assess commonalities that may help advance medical product development for rare diseases. #NIHChat
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA CBER’s Regenerative Medicine Advanced Therapy (RMAT) Designation Program aims to expedite the development & review of eligible regenerative medicine therapies intended for patients with unmet needs in serious conditions #NIHChat pic.twitter.com/DZ2dsnMtkf
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A5: In 2012, #FDA established the Patient-Focused Drug Development (#PFDD) initiative to more systematically obtain the patient perspective on specific diseases and their currently available treatments. To learn more, please visit: go.usa.gov/xEmsE pic.twitter.com/bWyY9hv3tu
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A5: #FDA publishes Rare Diseases: Common Issues in Drug Development Guidance for Industry Draft Guidance go.usa.gov/xEyqQ #NIHChat
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A5: #FDA/CDER awarded 5 Rare Pediatric Disease Priority Review Vouchers (PRV) in 2018 - #NIHChat
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A5: FDA provided funding on 9/1/18 to 5 Pediatric Device Consortia. Read More - go.usa.gov/xEmsA #NIHChat
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A5: #FDA funds $6M/yr for the Pediatric Device Consortia Grants Program – a program to provide advice and support services to advance innovation in medical devices for children. go.usa.gov/cpygz #NIHChat
	View conversation ·

	U.S. FDA @US_FDA	11h
	Replying to @US_FDA A5: #FDA issued a new RFA for FY2020 to support efficient and innovative clinical studies of products that address unmet needs in RDs or provide highly significant improvements in treatment or diagnosis. RFA due date is June 25, 2019. go.usa.gov/xEms6
	View conversation ·